Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celltrion CEO Cites Pfizer, J&J and Sanofi As Potential Buyers For Biosimilars Business

This article was originally published in PharmAsia News

Executive Summary

Although Korea’s Celltrion is not in takeover talks yet, CEO Seo Jung-jin named potential buyers after announcing he would sell his stake in the company he founded. Celltrion is expecting approval shortly in Europe for a biosimilar of J&J’s Remicade.

You may also be interested in...

Biosimilars: Is The Game About To Change In Europe?

Seven years since the first biosimilar hit the European market, these almost-copies have clearly disappointed. Now, though, momentum is building. Attitudes and regulations are slowly changing as cost-pressures continue – with implications for the U.S. And they’re doing so just as regulators review biosimilar Remicade, the first of a potentially far more lucrative set of copycat biologics.

Korea Biosimilars Leader Celltrion Shrugs Off Accounting Controversy, Focuses on Growth

SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts